Final Report - A Phase 2b, Randomized, Observer- Blinded Trial to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on 2 Different Dosing Schedules in Healthy Participants ≥11 to <15 Years of Age

Final Report - A Phase 2b, Randomized, Observer- Blinded Trial to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on 2 Different Dosing Schedules in Healthy Participants ≥11 to <15 Years of Age chavak11 Tue, 04/14/2026 - 07:02 Neisseria meningitidis Groups A, B, C, W, and Y Vaccine (MenABCWY) PF-06886992 PHASE II Wed, 06/17/2020 - 12:00 Fri, 01/05/2024 - 12:00 NCT04440176 C3511004 Public Disclosure Synopsis .pdf (263.23 KB) N https://clinicaltrials.gov/study/NCT04440176?term=C3511004&viewType=Card&rank=1 C3511004